These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 21633647)

  • 1. Optimized management of advanced hepatocellular carcinoma: four long-lasting responses to sorafenib.
    Abbadessa G; Rimassa L; Pressiani T; Carrillo-Infante C; Cucchi E; Santoro A
    World J Gastroenterol; 2011 May; 17(19):2450-3. PubMed ID: 21633647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term results of sorafenib in advanced-stage hepatocellular carcinoma: what can we learn from routine clinical practice?
    Sacco R; Bargellini I; Ginanni B; Bertini M; Faggioni L; Federici G; Romano A; Bertoni M; Metrangolo S; Altomare E; Parisi G; Tumino E; Scaramuzzino A; Bresci G; Bartolozzi C
    Expert Rev Anticancer Ther; 2012 Jul; 12(7):869-75. PubMed ID: 22845401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib.
    Lee JH; Park JY; Kim DY; Ahn SH; Han KH; Seo HJ; Lee JD; Choi HJ
    Liver Int; 2011 Sep; 31(8):1144-9. PubMed ID: 21745288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical response after sorafenib for hepatocellular carcinoma in elderly patients: a report of two cases.
    Spada F; Squadroni M; Lorizzo K; Farris A; Fazio N
    Tumori; 2012; 98(2):53e-56e. PubMed ID: 22678005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained treatment response of metastatic hepatocellular carcinoma with bevacizumab and sorafenib.
    Wich C; Agaimy A; Strobel D; Wissniowski TT; Hartmann A; Ocker M
    World J Gastroenterol; 2010 Jul; 16(28):3592-6. PubMed ID: 20653070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computed tomography findings of sorafenib-treated hepatic tumors in patients with advanced hepatocellular carcinoma.
    Kim MJ; Choi JI; Lee JS; Park JW
    J Gastroenterol Hepatol; 2011 Jul; 26(7):1201-6. PubMed ID: 21371120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial.
    Abou-Alfa GK; Johnson P; Knox JJ; Capanu M; Davidenko I; Lacava J; Leung T; Gansukh B; Saltz LB
    JAMA; 2010 Nov; 304(19):2154-60. PubMed ID: 21081728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Our experience of the treatment with sorafenib for unresectable hepatocellular carcinoma].
    Ishizaki M; Kaibori M; Matsui K; Nakatake R; Matsushima H; Sakaguchi T; Kwon AH
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):2493-5. PubMed ID: 22202424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A long-lasting response to sorafenib treatment in an advanced hepatocellular carcinoma patient.
    Di Lorenzo G; Imbimbo M; Leopardo D; Marciano R; Federico P; Buonerba C; Salvatore B; Marinelli A; Palmieri G
    Int J Immunopathol Pharmacol; 2010; 23(3):951-4. PubMed ID: 20943068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sorafenib therapy in patients with hepatocellular carcinoma before liver transplantation.
    Rowe IA
    Hepatology; 2010 Sep; 52(3):1171-2. PubMed ID: 20812364
    [No Abstract]   [Full Text] [Related]  

  • 11. Sorafenib for the treatment of advanced hepatocellular carcinoma.
    Connock M; Round J; Bayliss S; Tubeuf S; Greenheld W; Moore D
    Health Technol Assess; 2010 May; 14 Suppl 1():17-21. PubMed ID: 20507799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and effectiveness of sorafenib in patients with hepatocellular carcinoma in clinical practice.
    Di Costanzo GG; Tortora R; Iodice L; Lanza AG; Lampasi F; Tartaglione MT; Picciotto FP; Mattera S; De Luca M
    Dig Liver Dis; 2012 Sep; 44(9):788-92. PubMed ID: 22579445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.
    Edeline J; Boucher E; Rolland Y; Vauléon E; Pracht M; Perrin C; Le Roux C; Raoul JL
    Cancer; 2012 Jan; 118(1):147-56. PubMed ID: 21713764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sunitinib in patients with advanced hepatocellular carcinoma after progression under sorafenib treatment.
    Wörns MA; Schuchmann M; Düber C; Otto G; Galle PR; Weinmann A
    Oncology; 2010; 79(1-2):85-92. PubMed ID: 21071995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiologic complete response with sirolimus and sorafenib in a hepatocellular carcinoma patient who relapsed after orthotopic liver transplantation.
    Kim R; Aucejo F
    J Gastrointest Cancer; 2011 Mar; 42(1):50-3. PubMed ID: 20714941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What is the indication for sorafenib in hepatocellular carcinoma? A clinical challenge.
    Kim R; Byrne MT; Tan A; Aucejo F
    Oncology (Williston Park); 2011 Mar; 25(3):283-91, 295. PubMed ID: 21548473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selection of patients with hepatocellular carcinoma for sorafenib.
    Abou-Alfa GK
    J Natl Compr Canc Netw; 2009 Apr; 7(4):397-403. PubMed ID: 19406040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
    Cheng AL; Kang YK; Chen Z; Tsao CJ; Qin S; Kim JS; Luo R; Feng J; Ye S; Yang TS; Xu J; Sun Y; Liang H; Liu J; Wang J; Tak WY; Pan H; Burock K; Zou J; Voliotis D; Guan Z
    Lancet Oncol; 2009 Jan; 10(1):25-34. PubMed ID: 19095497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib in hepatocellular carcinoma.
    Josephs DH; Ross PJ
    Br J Hosp Med (Lond); 2010 Aug; 71(8):451-6. PubMed ID: 20852487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib use in hepatocellular carcinoma in Japan: early experience and impact on clinical practice.
    Zhu AX
    Clin Drug Investig; 2012 Aug; 32 Suppl 2():1-2. PubMed ID: 22873622
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.